Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the 50-50 cell-therapy-focused joint venture with Fosun Pharma.

The FDA has approved Kite Pharma's Tecartus as a treatment for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL), making CAR-T therapy an option for an ...

As cell therapies continue to advance, the need for better automated, large-scale manufacturing options increases.

The new CEO — formerly of Kite Pharma and Genentech — will receive an annual salary of $625,000 plus a one-time bonus of $650,000. Peter Maag, who led cell therapy company Kyverna Therapeutics ...

AstraZeneca and Daiichi Sankyo's Dato-DXd failed to improve survival in a breast cancer study. Gilead Sciences' Kite will bow ...

The path forward is clear: employers must evaluate their health plan the same way they do their Saturday shopping excursion.

Kite Pharma has filed its CAR-T cancer therapy in Europe in certain types of non-Hodgkin lymphoma, hoping to get to market ahead of close rival Novartis with some impressive efficacy data.

Meacham recently attended Gilead's cell therapy event, and he says the potential scalability of Gilead subsidiary Kite Pharma's cell therapy business is impressive. He is confident in Gilead's ...

Arcellx’s strategic partnership with Kite Pharma validates its technology, potentially leading to milestone payments of up to $935 million. Anito-cel’s Phase 3 trial results are expected by ...

LAST YEAR: NEW CHANGE: NA AGE: 75 RESIDENCE: Bel Air SOURCE OF WEALTH: Pharmaceutical company sales ...

Although details are scant, Shanghai Fosun Pharmaceutical Co. Ltd. plans to buy out partner Kite Pharma Inc. (now Gilead Sciences Inc.) in the Fosun Pharma Kite Biotechnology Co. Ltd. joint venture ...

This immunotherapy company is taking the body’s T cells, which naturally fight infections, and engineering them to fight cancer. It is farthest along with its therapy for aggressive non-Hodgkin ...